Our Research & Development

GL-MULO-00156 | November 2025

Sort

CEACAM5

ADC

Learn about how Merck is investigating carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) as a target for anticancer therapy

10 Min

PD-L1 Targeting

IO

Learn about Merck’s research into immuno-oncology medicines that harness the patient’s immune system to fight cancer, including targeting programmed death-ligand 1 (PD-L1)

10 Min

TIGIT Targeting

IO

Learn about Merck’s research into immuno-oncology medicines that harness the patient’s immune system to fight cancer, including targeting T-cell immunoglobulin and ITIM domain (TIGIT)

10 Min